MarketLens

Abbott's Dual-Analyte Bet Positions It to Outpace Dexcom in the Expanding CGM Market

1 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Amazon's Strategic Play in Africa: Leveraging Regulatory Hurdles to Outpace Starlink

1 months ago

What Should Investors Expect from DexCom's Upcoming Q1 Earnings

4 months ago

Cheniere Energy: Geopolitical Tailwinds Outpace Political Headwinds

1 months ago

Why is Tether Gold (XAUt) Expanding to BNB Chain Now

5 months ago

Insulet Reports Second Quarter 2026 Results

Insulet's Q2 2026 revenue rose 23.5% to $801.7M, beating its 20%-22% constant-currency guidance, driven by Omnipod sales of $795.9M.

PODD

Stock News•4 weeks ago

Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends

Abbott is expanding across diabetes care, oncology diagnostics and heart devices via new launches and acquisitions, creating multiple growth paths.

ABT

Stock News•1 months ago

Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes

Dexcom G7 15 Day CGM received Health Canada authorization for adults 18+, extending wear to an industry-leading 15.5 days with real-time glucose readings.

DXCM

Stock News•1 months ago

DexCom: The Growth Thesis Still Needs To Be Proven

DexCom faces a pivotal transition as GLP-1 adoption threatens its core insulin-treated diabetes market. At 28x earnings, valuation offers limited upside until CGM adoption in Type 2 non-insulin patien...

DXCM